295
Participants
Start Date
September 30, 2010
Primary Completion Date
September 30, 2011
Study Completion Date
September 30, 2011
TC-5214
Tablet, oral, twice daily for 8 weeks
Placebo
Tablet, oral, twice daily for 8 weeks
Research Site, Brno
Research Site, Kutná Hora
Research Site, Litoměřice
Research Site, Pilsen
Research Site, Prague
Research Site, Praha 10 - Strasnice
Research Site, Tartu
Research Site, Dublin
Research Site, Tallinn
Research Site, Tartu
Research Site, Võru
Research Site, Dublin
Research Site, Espoo
Research Site, Helsinki
Research Site, Kuopio
Research Site, Mikkeli
Research Site, Oulu
Research Site, Tampere
Research Site, Toulon
Research Site, Douai
Research Site, Dublin
Research Site, Élancourt
Research Site, Jarnac
Research Site, La Seyne-sur-Mer
Research Site, Nîmes
Research Site, Rennes
Research Site, Toulon
Research Site, Villejuif
Research Site, Mainz
Research Site, Berlin
Research Site, Bochum
Research Site, Dublin
Research Site, Siegen
Research Site, Dublin
Research Site, Dublin
Research Site, Jelgava
Research Site, Liepāja
Research Site, Riga
Research Site, Sigulda
Research Site, Strenči
Research Site, Ziegzdrai
Research Site, Kaunas
Research Site, Vilnius
Research Site, Dublin
Research Site, Palanga
Research Site, Šilutė
Research Site, Vilnius
Research Site, Gdynia
Research Site, Leszno
Research Site, Bełchatów
Research Site, Bialystok
Research Site, Bydgoszczy
Research Site, Dublin
Research Site, Gdansk
Research Site, Lublin
Research Site, Sosnowiec
Research Site, Torun
Research Site, Toru
Research Site, Żuromin
Research Site, Dublin
Research Site, Gothenburg
Research Site, Halmstad
Research Site, Lund
Research Site, Malmo
Research Site, Solna
Research Site, Stockholm
Lead Sponsor
Targacept Inc.
INDUSTRY
AstraZeneca
INDUSTRY